Altaris Acquires WuXi AppTec's Advanced Therapies U.S. and U.K. Operations (including OXGENE)
December 24, 2024
Altaris, a New York-based healthcare-focused investment firm, acquired the U.S. and U.K. operations of WuXi AppTec's Advanced Therapies unit (including OXGENE). Advanced Therapies will be renamed and headquartered in the United States and Altaris intends to combine it with its recently acquired Minaris Regenerative Medicine to form Minaris Advanced Therapies, expanding cell-therapy CDMO capabilities and global footprint.
- Buyers
- Altaris, LLC
- Targets
- Advanced Therapies (U.S. and U.K. operations of WuXi AppTec's Advanced Therapies Unit), OXGENE
- Sellers
- WuXi AppTec
- Platforms
- Minaris Regenerative Medicine
- Industry
- Biotechnology
- Location
- Pennsylvania, United States
- Transaction Type
- Addon
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.